Details
Stereochemistry | ACHIRAL |
Molecular Formula | 18CN.7Fe |
Molecular Weight | 859.228 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Fe++].[Fe++].[Fe++].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N
InChI
InChIKey=DCYOBGZUOMKFPA-UHFFFAOYSA-N
InChI=1S/18CN.7Fe/c18*1-2;;;;;;;/q18*-1;3*+2;4*+3
Molecular Formula | Fe |
Molecular Weight | 55.845 |
Charge | 3 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | CHN |
Molecular Weight | 27.0253 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | Fe |
Molecular Weight | 55.845 |
Charge | 2 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.drugfuture.com/chemdata/ferroglycine-sulfate.htmlhttp://nj.gov/health/eoh/rtkweb/documents/fs/0928.pdfhttps://www.drugs.com/inactive/ferrous-oxide-389.htmlhttp://www.druglead.com/cds/ferrous-iodide.htmlhttps://www.ncbi.nlm.nih.gov/pubmed/16694502http://www.foodchemadditives.com/products/Ferrous-Lactatehttps://www.ncbi.nlm.nih.gov/pubmed/14116934DOI: 10.1021/ja00949a016 Retrived from http://pubs.acs.org/doi/abs/10.1021/ja00949a016Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/3541174 | https://books.google.ru/books?id=7mxyBgAAQBAJ&pg=PA13&lpg=PA13&dq=%22ferrous+iodide%22+anemia&source=bl&ots=ZGyFhUiJZ4&sig=IZOhRVaGmlwX7GcqgoE6rnCsCa4&hl=ru&sa=X&ved=0ahUKEwjYu7PCyYHUAhWiQpoKHR6cCfcQ6AEIUjAJ#v=onepage&q=%22ferrous%20iodide%22&f=false
Sources: http://www.drugfuture.com/chemdata/ferroglycine-sulfate.htmlhttp://nj.gov/health/eoh/rtkweb/documents/fs/0928.pdfhttps://www.drugs.com/inactive/ferrous-oxide-389.htmlhttp://www.druglead.com/cds/ferrous-iodide.htmlhttps://www.ncbi.nlm.nih.gov/pubmed/16694502http://www.foodchemadditives.com/products/Ferrous-Lactatehttps://www.ncbi.nlm.nih.gov/pubmed/14116934DOI: 10.1021/ja00949a016 Retrived from http://pubs.acs.org/doi/abs/10.1021/ja00949a016
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/3541174 | https://books.google.ru/books?id=7mxyBgAAQBAJ&pg=PA13&lpg=PA13&dq=%22ferrous+iodide%22+anemia&source=bl&ots=ZGyFhUiJZ4&sig=IZOhRVaGmlwX7GcqgoE6rnCsCa4&hl=ru&sa=X&ved=0ahUKEwjYu7PCyYHUAhWiQpoKHR6cCfcQ6AEIUjAJ#v=onepage&q=%22ferrous%20iodide%22&f=false
There is no information about biological and pharmacological application of Iron(II) fluoride (also known as ferrous fluoride). It is known, that this substance is used to catalyze some organic reactions.
Originator
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
|||
Primary | Ferro Sanol Duodenal Approved UseFerro Sanol is an iron substitute in case of latent or manifest iron deficiency with and without development of anaemia. |
|||
Curative | RADIOGARDASE Approved UseInsoluble Prussian blue is indicated for treatment of patients with known or suspected internal contamination with radioactive cesium and/or radioactive or non-radioactive thallium to increase their rates of elimination. Launch Date2003 |
|||
PubMed
Title | Date | PubMed |
---|---|---|
FERROUS IODIDE AS A SUBSTITUTE FOR VITAMIN A IN RATS. | 1932 Jul 1 |
|
[FERROUS ASPARTATE IN THERAPY]. | 1964 Jan 1 |
|
Endothelial dysfunction and inflammation induced by iron oxide nanoparticle exposure: Risk factors for early atherosclerosis. | 2011 Jun 10 |
|
Reactivity enhancement of iron sulfide nanoparticles stabilized by sodium alginate: Taking Cr (VI) removal as an example. | 2017 Jul 5 |
|
Continuous sulfidogenic wastewater treatment with iron sulfide sludge oxidation and recycle. | 2017 May 1 |
Sample Use Guides
Adults should usually take one capsule a day. In cases of pronounced iron deficiency, adults can be given a dosage 2 to 3 times higher at the beginning of therapy. A daily dose of more than 5 mg Fe2+/kg body weight should in-well founded exceptional cases not be exceeded.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:05:35 GMT 2025
by
admin
on
Mon Mar 31 18:05:35 GMT 2025
|
Record UNII |
TLE294X33A
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
169203
Created by
admin on Mon Mar 31 18:05:35 GMT 2025 , Edited by admin on Mon Mar 31 18:05:35 GMT 2025
|
||
|
FDA ORPHAN DRUG |
173403
Created by
admin on Mon Mar 31 18:05:35 GMT 2025 , Edited by admin on Mon Mar 31 18:05:35 GMT 2025
|
||
|
WHO-ATC |
V03AB31
Created by
admin on Mon Mar 31 18:05:35 GMT 2025 , Edited by admin on Mon Mar 31 18:05:35 GMT 2025
|
||
|
NCI_THESAURUS |
C360
Created by
admin on Mon Mar 31 18:05:35 GMT 2025 , Edited by admin on Mon Mar 31 18:05:35 GMT 2025
|
||
|
NDF-RT |
N0000192801
Created by
admin on Mon Mar 31 18:05:35 GMT 2025 , Edited by admin on Mon Mar 31 18:05:35 GMT 2025
|
||
|
WHO-VATC |
QV03AB31
Created by
admin on Mon Mar 31 18:05:35 GMT 2025 , Edited by admin on Mon Mar 31 18:05:35 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB13839MIG
Created by
admin on Mon Mar 31 18:05:35 GMT 2025 , Edited by admin on Mon Mar 31 18:05:35 GMT 2025
|
PRIMARY | |||
|
QQ-28
Created by
admin on Mon Mar 31 18:05:35 GMT 2025 , Edited by admin on Mon Mar 31 18:05:35 GMT 2025
|
PRIMARY | |||
|
8665
Created by
admin on Mon Mar 31 18:05:35 GMT 2025 , Edited by admin on Mon Mar 31 18:05:35 GMT 2025
|
PRIMARY | |||
|
7127
Created by
admin on Mon Mar 31 18:05:35 GMT 2025 , Edited by admin on Mon Mar 31 18:05:35 GMT 2025
|
PRIMARY | |||
|
PRUSSIAN BLUE
Created by
admin on Mon Mar 31 18:05:35 GMT 2025 , Edited by admin on Mon Mar 31 18:05:35 GMT 2025
|
PRIMARY | |||
|
539399
Created by
admin on Mon Mar 31 18:05:35 GMT 2025 , Edited by admin on Mon Mar 31 18:05:35 GMT 2025
|
PRIMARY | |||
|
237-875-5
Created by
admin on Mon Mar 31 18:05:35 GMT 2025 , Edited by admin on Mon Mar 31 18:05:35 GMT 2025
|
PRIMARY | |||
|
DTXSID9047756
Created by
admin on Mon Mar 31 18:05:35 GMT 2025 , Edited by admin on Mon Mar 31 18:05:35 GMT 2025
|
PRIMARY | |||
|
24902
Created by
admin on Mon Mar 31 18:05:35 GMT 2025 , Edited by admin on Mon Mar 31 18:05:35 GMT 2025
|
ALTERNATIVE | |||
|
100000078741
Created by
admin on Mon Mar 31 18:05:35 GMT 2025 , Edited by admin on Mon Mar 31 18:05:35 GMT 2025
|
PRIMARY | |||
|
4860
Created by
admin on Mon Mar 31 18:05:35 GMT 2025 , Edited by admin on Mon Mar 31 18:05:35 GMT 2025
|
PRIMARY | |||
|
TLE294X33A
Created by
admin on Mon Mar 31 18:05:35 GMT 2025 , Edited by admin on Mon Mar 31 18:05:35 GMT 2025
|
PRIMARY | |||
|
m9288
Created by
admin on Mon Mar 31 18:05:35 GMT 2025 , Edited by admin on Mon Mar 31 18:05:35 GMT 2025
|
PRIMARY | Merck Index | ||
|
DB06783
Created by
admin on Mon Mar 31 18:05:35 GMT 2025 , Edited by admin on Mon Mar 31 18:05:35 GMT 2025
|
PRIMARY | |||
|
61711
Created by
admin on Mon Mar 31 18:05:35 GMT 2025 , Edited by admin on Mon Mar 31 18:05:35 GMT 2025
|
PRIMARY | |||
|
C47532
Created by
admin on Mon Mar 31 18:05:35 GMT 2025 , Edited by admin on Mon Mar 31 18:05:35 GMT 2025
|
PRIMARY | |||
|
14038-43-8
Created by
admin on Mon Mar 31 18:05:35 GMT 2025 , Edited by admin on Mon Mar 31 18:05:35 GMT 2025
|
PRIMARY | |||
|
TLE294X33A
Created by
admin on Mon Mar 31 18:05:35 GMT 2025 , Edited by admin on Mon Mar 31 18:05:35 GMT 2025
|
PRIMARY | |||
|
30069
Created by
admin on Mon Mar 31 18:05:35 GMT 2025 , Edited by admin on Mon Mar 31 18:05:35 GMT 2025
|
PRIMARY | |||
|
CHEMBL2096629
Created by
admin on Mon Mar 31 18:05:35 GMT 2025 , Edited by admin on Mon Mar 31 18:05:35 GMT 2025
|
PRIMARY | |||
|
C000170
Created by
admin on Mon Mar 31 18:05:35 GMT 2025 , Edited by admin on Mon Mar 31 18:05:35 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
PARENT -> SALT/SOLVATE | |||
|
PARENT -> SALT/SOLVATE |